Analytical Data
-
Gene name
BRAP
-
简介
BRAP protein acts as a negative regulator of MAP kinase activation, inhibits the formation of the Raf/MEK complex, and may inactivate the KSR1 scaffolding protein. As a Ras-responsive E3 ubiquitin ligase, BRAP undergoes autopolyubiquitination upon Ras activation, releasing its inhibitory effect on Raf/MEK complex formation. BRAP Protein, Human is the recombinant human-derived BRAP protein, expressed by E. coli , with tag free.
- Application
-
Alternative Names
BRAP; BRCA1-associated protein; BRAP2; Impedes mitogenic signal propagation; IMP; RING finger protein 52; RING-type E3 ubiquitin transferase BRAP2; Renal carcinoma antigen NY-REN-63
-
Species
Human
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7Z569
-
Expression Region
S2-K592
-
Protein Length
Partial
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Related Products
Protein Description
BRAP (BRAF-activating protein) is a crucial player in the regulation of the MAPK signaling pathway, which is vital for cell proliferation, differentiation, and survival. Given its role in modulating BRAF activity, abnormal regulation of BRAP is implicated in various cancers, especially melanoma, where BRAF mutations are prevalent. Research into BRAP-recombinant proteins has gained momentum as scientists aim to better understand its function and interactions within signaling networks. These recombinant proteins facilitate the exploration of BRAP’s structural characteristics, along with its binding affinities and mechanisms of action. By utilizing molecular biology techniques like gene cloning and protein expression, researchers can produce large quantities of BRAP for biochemical assays and therapeutic applications. Moreover, the study of BRAP-recombinant proteins opens avenues for targeted cancer therapies, wherein interventions can be designed to correct BRAP dysregulation or to exploit its pathways for cancer treatment. Additionally, insights gained from BRAP research may contribute to the development of diagnostic tools or biomarkers for cancer prognosis. Overall, the investigation of BRAP-recombinant proteins holds promise for advancing our understanding of cancer biology and developing novel therapeutic strategies.
